medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2017, Número 1

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2017; 15 (1)


Uso de metotrexato, azatioprina y micofenolato de mofetilo en dermatología

Saldaña M, Torres-Camacho P, Arellano MMI

Idioma: Español
Referencias bibliográficas: 83
Paginas: 45-54
Archivo PDF: 337.69 Kb.


RESUMEN

Los inmunosupresores son aquellos fármacos que tienen la capacidad de inhibir el funcionamiento del sistema inmunológico. En las últimas décadas se han incorporado al arsenal terapéutico dermatológico, permitiendo disminuir el uso de corticoides así como intensificar la terapéutica. En este artículo se hace una revisión de las propiedades farmacológicas y las diferentes indicaciones terapéuticas de tres de los principales inmunomoduladores utilizados en dermatología: azatioprina, metotrexato, micofenolato de mofetilo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gubner R. Effect of “aminopterine” on epithelial tissues, Arch Dermatol Syphiol 1951; 64: 688-99.

  2. Edmundson WF y Guy WB. Treatment of psoriasis with folic acid antagonists, ama Arch Derm 1958; 78: 200-3.

  3. Roenigk Jr HH, Maibach HI y Weinstein GD. Use of methotrexate in psoriasis, Arch Dermatol 1972; 105: 363-5.

  4. Serrano P y Mascaró J. Metotrexato: actualización en el tratamiento de la psoriasis, Piel 2006; 21: 358-63.

  5. Smith K, Daniel Su WP y Muller S. Methotrexate in dermatology, Derm Sinica 1989; 7: 11-8.

  6. Puig L. Metotrexato: novedades terapéuticas, Actas Dermosifiliogr 2014; 105: 583-9.

  7. Kremer JM, Galivan J, Streckfuss A y Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates, Arthritis Rheum 1986; 29: 832-5.

  8. Carretero-Hernández G. Metotrexato en psoriasis: ¿es necesaria una dosis de prueba?, Actas Dermosifiliogr 2012; 103: 1-4.

  9. Saurat JH, Stingl G, Dubertret L et al. champion Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (champion), Br J Dermatol 2008; 158: 558-66.

  10. Barker J, Hoffmann M, Wozel G et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (restore1), Br J Dermatol 2011; 165: 1109-17.

  11. Reich K, Langley RG, Papp KA et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis, N Engl J Med 2011; 365: 1586-96.

  12. Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis, N Engl J Med 2003; 349: 658-65.

  13. West J, Ogston S y Foerster J. Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials, plos one 2016; 11(5): e0153740, doi: 10.1371/journal.pone.0153740.

  14. Hammerschmidt M y Mulinari-Brenner F. Efficacy and safety of methotrexate in alopecia areata, An Bras Dermatol 2014; 89: 729-34.

  15. Droitcourt C, Milpied B, Ezzedine K et al. Interest of high-dose pulse corticosteroid therapy combined with methotrexate for severe alopecia areata: a retrospective case series, Dermatology 2012; 224: 369-73.

  16. Lucas P, Bodemer C, Barbarot S et al. Methotrexate in severe childhood alopecia areata: long-term follow-up, Acta Derm Venereol 2016; 96: 102-3.

  17. Villalba L, Hicks JE, Adams EM et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens, Arthritis Rheum 1998; 41: 392-8.

  18. Vencovsk J, Jarosová K, Machácek S et al. Cyclosporine a versus methotrexate in the treatment of polymyositis and dermatomyositis, Scand J Rheumatol 2000; 29: 95-102.

  19. Pérez Pelegay J, Charro Martínez L, Grasa Jordán MP y Carapeto Márquez .J. Pitiriasis liquenoide, Med Cutan Iber Lat Am 2007; 35: 167-73.

  20. Romani J, Puig LL, Fernéndez-Filgueras MT y De Moragas JM. Pityriasis lichenoides in children: clinicopathologic review of 22 patients, Pediatr Dermatol 1998; 15: 1-6.

  21. Castellanos-Íñiguez AA y Guevara Gutiérrez E. Pénfigo vulgar, Dermatol Rev Mex 2011; 55: 73-83.

  22. Sánchez-Pérez J y García-Díez A. Pénfigo, Actas Dermosifiliogr 2005; 96: 329-56.

  23. Fuertes de Vega P, Iranzo-Fernández B y Mascaró-Galy JM. Penfigoide ampolloso: guía de manejo práctico, Actas Dermosifiliogr 2014; 105: 328-34.

  24. Carretero G, Puig L, Dehesa L et al. Metotrexato: guía de psoriasis, Actas Dermosifiliogr 2010; 101: 600-13.

  25. Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents, J Am Acad Dermatol 2009; 61: 451-85.

  26. Chalmers RJ, Kirby B y Smith A. Replacement of routine liver biopsy by procollagen iii aminopeptide for monitoring patients with psoriasis receiving longterm methotrexate: a multicentre audit and health economic analysis, Br J Dermatol 2005; 152: 443-9.

  27. Maurice PDL, Maddox AJ y Green CA. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminale peptide of type ii procollagen, Br J Dermatol 2005; 152: 450-7.

  28. Guillaume JC. Méthotrexate dans le psoriasis: les biopsies hépatiques itératives sont-elles encore nécessaires?, Ann Dermatol Venereol 2006; 133: 513-7.

  29. Lanse SB, Arnold GL, Gowans JD y Kaplan MM. Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/benefit ratio, Dig Dis Sci 1985; 30: 104-9.

  30. Aithal GP, Haugk B, Das S et al. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?, Aliment Pharmatol Ther 2004; 19: 391-9.

  31. Carrión J. Utilidad del Fibroscan® para evaluar la fibrosis hepática, Gastroenterol Hepatol 2009; 32: 415-23.

  32. Mendoza J, Gómez-Domínguez E y Moreno-Otero R. Elastografía de transición (Fibroscan®), un nuevo método no invasivo en la valoración de la fibrosis hepática, Med Clin Barc 2006; 126: 220-1.

  33. Barbero-Villares A, Mendoza J, Trapero-Marugan M et al. Evaluation of liver fibrosis by transient elastography in methotrexate treated patients, Med Clin Barc 2011; 137: 637-9.

  34. Patel A, Swerlick R y McCall CO. Azathioprine in dermatology: the past, the present, and the future, J Am Acad Dermatol 2006; 55: 369-89.

  35. Wise M y Callen J. Azathioprine: a guide for the management of dermatology patients, Dermatol Therapy 2007; 20: 206-15.

  36. Sanderson J, Ansari A, Marinaki T y Duley J. Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?, Ann Clin Biochem 2004; 41: 294-302.

  37. Szumlanski C, Otterness D, Her C et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism, dna Cell Biol 1996; 15: 17-30.

  38. Schwab M, Schaffeler E y Marx C. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine s-methyltransferase polymorphism, Pharmacogenetics 2002; 12: 429-36.

  39. Jackson AP, Hall AG y McLelland J. Thiopurine methyltransferase levels should be measured before commencing patients on azathioprine, Br J Dermatol 1997; 136: 133-4.

  40. Marra CA, Esdaile JM y Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine, J Rheumatol 2002; 29: 2507-12.

  41. Martel RM, Melwani P, Islas D et al. Safety of azathioprine therapy adjusted to thiopurine methyltransferase activity in the treatment of infantile atopic dermatitis. Report on 7 cases, Actas Dermosifiliogr 2010; 101: 415-20.

  42. Caufield M y Wynnis T. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring, J Am Acad Dermatol 2013; 68: 29-35.

  43. Roenigk HH Jr y Deodhar S. Pemphigus treatment with azathioprine. Clinical and immunologic correlation, Arch Dermatol 1973; 107: 353-7.

  44. Ljubojevic S, Lipozenci J, Brenner S y Budimci D. Pemphigus vulgaris: a review of treatment over a 19-year period, J Eur Acad Dermatol Venereol 2002; 16: 599-603.

  45. Ahmed AR, Maize JC y Provost TT. Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy, Arch Dermatol 1977; 113: 1043-6.

  46. Greaves MW, Burton JL, Marks J y Dawber RP. Azathioprine in treatment of bullous pemphigoid, Br Med J 1971; 1: 144-5.

  47. Mondino BJ y Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid, Am J Ophthalmol 1983; 96: 453-9.

  48. Ginzler E, Sharon E, Diamond H y Kaplan D. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus, Arthritis Rheum 1975; 18: 27-34.

  49. Swaak AJ, Statius van Eps LW, Aarden LA y Feltkamp TE. Azathioprine in the treatment of systemic lupus erythematosus. A three-year prospective study, Clin Rheumatol 1984; 3: 285-91.

  50. Bunch TW, Worthington JW, Combs JJ et al. Azathioprine with prednisone for polymyositis. A controlled, clinical trial, Ann Intern Med 1980; 92: 365-9.

  51. Hafeez Z.H. Unusual presentation of cutaneous vasculitis, Int J Dermatol 1998; 37: 687-90.

  52. Carlson JA, Cavaliere LF y Grant-Kels JM. Cutaneous vasculitis: diagnosis and management, Clin Dermatol 2006; 24: 414-29.

  53. Berth-Jones J, Takwale A, Tan E et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial, Br J Dermatol 2002; 147: 324-30.

  54. Du Vivier A, Munro DD y Verbov J. Treatment of psoriasis with azathioprine, Br Med J 1974; 1: 49-51.

  55. Hacker SM, Ramos-Caro FA, Ford MJ y Flowers FP. Azathioprine: a forgotten alternative for treatment of severe psoriasis, Int J Dermatol 1992; 31: 873-4.

  56. Woolfson H. Acne fulminans with circulating immune complexes and leukaemoid reaction treated with steroids and azathioprine, Clin Exper Dermatol 1987; 12: 463-6.

  57. Hunter GA y Forbes IJ. Treatment of pityriasis rubra pilaris with azathioprine, Br J Dermatol 1972; 87: 42-5.

  58. Lear JT y English JS. Erosive and generalized lichen planus responsive to azathioprine, Clin Exper Dermatol 1996; 21: 56-7.

  59. Calin A. A placebo controlled, crossover study of azathioprine in Reiter’s syndrome, Ann Rheum Dis 1986; 45: 653-5.

  60. Kennedy DT, Hayney MS y Lake KD. Azathioprine and allopurinol: the price of an avoidable drug interaction, Ann Pharmacother 1996; 30: 951-4.

  61. El-Gamel A, Evans C y Keevil B. Effect of allopurinol on the metabolism of azathioprine in heart transplant patients, Transplant Proc 1998; 30: 1127-9.

  62. Cummins D, Sekar M, Halil O y Banner N. Myelosuppression associated with azathioprine–allopurinol interaction after heart and lung transplantation, Transplantation 1996; 61: 1661-2.

  63. Dewit O, Vanheuverzwyn R, Desager JP y Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn’s disease, Aliment Pharmacol Ther 2002; 16: 79-85.

  64. Gossmann J, Kachel HG, Schoeppe W y Scheuermann EH. Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors, Transplantation 1993; 56: 585-9.

  65. Bradley PP, Warden GD, Maxwell JG y Rothstein G. Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim- sulfamethoxazole, Ann Intern Med 1980; 93: 560-2.

  66. Jones JJ y Ashworth J. Azathioprine-induced shock in dermatology patients, J Am Acad Dermatol 1993; 29: 795-6.

  67. Gardiner SJ y Begg EJ. Pharmacogenetics testing for drug metabolizing enzymes: is it happening in practice?, Pharmacogen Genomics 2005; 15: 365-9.

  68. Hadda V, Pandey BD, Gupta R y Goel A. Azathioprine induced pancytopenia: a serious complication, J Postgrad Med 2009; 55: 139-40.

  69. Sinico RA, Sabadini E, Borlandelli S et al.. Azathioprine hypersensitivity: report of two cases and review of the literature, J Nephrol 2003; 16: 272-6.

  70. Nero P, Rahman A. e Isenberg DA. Does long term treatment with azathioprine predispose to malignancy and death in patients with systemic lupus erythematosus?, Ann Rheum Dis 2004; 63: 325-6.

  71. Silman AJ, Petrie J, Hazleman B y Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20-year follow-up study, Ann Rheum Dis 1988; 47: 988-92.

  72. Robles AL, De la O M y Reynoso J. Clinical pharmacology and therapeutic drug monitoring of immunosuppressive agents, en T Rath (ed), Current Issues and Future Direction in Kidney Transplantation, InTech, Croacia, 2013, pp. 309-42.

  73. Rathee P, Chaudhary H, Rathee S et al. Immunosupressants: a review, Pharma Innovation 2013; 1: 90-9.

  74. Allevato M y Donatti L. Mofetil micofenolato, Act Terap Dermatol 2006; 29: 222.

  75. Mydlarski PR. Mycophenolate mofetil: a dermatologic perspectiva, Skin Therapy Letter 2005; 10: 6.

  76. Strathie SJ y Tait C. Mycophenolic acid in dermatology a century after its discovery, Australas J Dermatol 2015; 56: 77-83.

  77. Lynch WS y Roenigk HH. Mycophenolic acid for psoriasis, Arch Dermatol 1977; 113: 1203-8.

  78. Linn Jones E, Epinette WW, Hackney VC. et al. Treatment of psoriasis with oral mycophenolic acid, J Invest Dermatol 1975; 65: 537-42.

  79. Gómez EC, Menéndez L y Frost P. Efficacy of mycophenolic acid for the treatment of psoriasis, J Am Acad Dermatol 1979; 1: 531-7.

  80. Liu V y Mackool BT. Mycophenolate in dermatology, J Dermatol Treat 2003; 14: 203-11.

  81. Orvis AK, Wesson SK, Breza TS. et al. Mycophenolate mofetil in dermatology, J Am Acad Dermatol 2009; 60: 183-99.

  82. Beissert S, Werfel T y Frieling U. A comparison of oral methyprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid, Arch Dermatol 2007; 143: 1536-42.

  83. Martin LK, Werth VP, Villanueva EV y Murrel D. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus, J Am Acad Dermatol 2010; 64: 903-8.




2020     |     www.medigraphic.com